Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali
- Address
- Via Franco Faggiana 1668, 04100 Latina, Italy
Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali
The Marco Pasquali Institute is a specialized clinical research center participating in diverse multi-center therapeutic trials across multiple medical disciplines. The institute demonstrates particular expertise in evaluating novel pharmaceutical interventions and surgical approaches for conditions ranging from neurological disorders to oncology and cardiovascular disease prevention.
- Migraine treatment and prevention, including acute therapy and menstrual migraine management with CGRP antagonists
- Urological oncology with focus on high-risk and oligometastatic prostate cancer surgical interventions
- Cardiovascular disease prevention strategies targeting atherosclerotic cardiovascular disease in high-risk populations
- Pelvic floor disorders including fecal incontinence treatment with regenerative cell therapy
The center's research portfolio reflects a commitment to advancing both surgical excellence and pharmacological innovation. Notable areas of investigation include the evaluation of atogepant for various migraine presentations, apalutamide combination therapy following radical prostatectomy in metastatic prostate cancer, and inclisiran for primary prevention of major adverse cardiovascular events. The institute also participates in innovative studies exploring cell-based therapies for sphincter dysfunction, demonstrating versatility across traditional surgical specialties and emerging regenerative medicine approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Novo Nordisk A/S1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization | Novo Nordisk A/S | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atogepant | 2 | Unknown | 2024-04-03 | 2025-03-05 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.